Maryland Momentum Fund and VTC Innovation Fund have both contributed to a series A round for Veralox Therapeutics, which is focusing on diseases with unmet needs.
Veralox Therapeutics, a US-based biotechnology developer advancing research from the US National Institutes of Health (NIH) and multiple universities, has completed a $16.6m series A round featuring Maryland Momentum Fund and VTC Innovation Fund.
The two funds, affiliated with University System of Maryland and Virginia Tech respectively, were joined by Hatteras Venture Partners, which led the round.
The transaction also attracted Sanofi Ventures, the corporate venturing arm of pharmaceutical firm Sanofi, and Alexandria Venture Investments, a vehicle for…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
